JPMorgan likes Boston Scientific’s risk/reward at current share levels and would be a buyer of the stock into the investor day. The firm expects positive estimate revisions into and throughout 2024 and sees an “excellent entry point” ahead of Sunday’s ADVENT pulsed field ablation data readout. It adds a “Positive Catalyst Watch” to Boston Scientific and keeps an Overweight rating on the name with a $60 price target, calling the company a top large cap idea.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BSX:
- Boston Scientific call volume above normal and directionally bullish
- Unusually active option classes on open July 31st
- Boston Scientific price target raised to $59 from $56 at Barclays
- Boston Scientific management to meet virtually with BTIG
- Boston Scientific price target raised to $61 from $60 at Raymond James